Showing results (361-370 of 654) with videos related to

Sort By:
Pageof 66
Molecular Cancer|March 27, 2024
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE studyBlessie Elizabeth Nelson, Jason Roszik, Jibran Ahmed, et al.
Targeted Oncology|September 24, 2021
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic CancerKathleen N Moore, David S Hong, Manish R Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive CancerMing Zhao, Stephen Scott, Kurt W Evans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2021
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or LymphomasFunda Meric-Bernstam, Randy F Sweis, F Stephen Hodi, et al.
Oncotarget|May 8, 2018
Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutationsNeeta Somaiah, Hannah C Beird, Andrea Barbo, et al.
Cancer|December 8, 2005
Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapyLinda J Adepoju, W Fraser Symmans, Gildy V Babiera, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trialsHossein Maymani, Kenneth Hess, Roman Groisberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2021
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid TumorsJames J Harding, Melinda Telli, Pamela Munster, et al.
Inflammation|February 27, 2019
Silymarin Restores Regulatory T Cells (Tregs) Function in Multiple Sclerosis (MS) Patients In VitroMaryam Shariati, Vahid Shaygannejad, Faezeh Abbasirad, et al.
Oncotarget|July 16, 2016
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenonKanwal Raghav, Van Morris, Chad Tang, et al.
Pageof 66